肺癌是人类最常见的肿瘤之一。目前用于肺癌早期筛查主要包括X线、胸部CT及血清肿瘤标志物(如癌胚抗原、神经元烯醇化酶、细胞角蛋白19片段等),但其敏感性及特异性均不尽人意。目前新发现的肿瘤相关自身抗体/抗原中,大部分并没有较好的敏感性。相比早期诊断,循环中肿瘤细胞在测预后中更有意义。有文献系统评价总结了在非小细胞肺癌中,治疗前和治疗后检测循环中肿瘤细胞对预后的HR值分别为2.61(1.82、3.74)或4.19 (2.92、6.00)。大量的研究提示血液、呼出气体及痰中蛋白组学、小核苷酸分子及DNA片段检测有较大潜力,尤其是检测血液不同组合的小核苷酸分子可能有更好的效果。现参考近年文献就新型肺癌早期检测的方式作一综述。
Citation: 麦琳,孙蓉菲,李为民. 肺癌早期诊断相关新型标志物的研究进展. West China Medical Journal, 2013, 28(3): 466-472. doi: 10.7507/1002-0179.20130152 Copy
1. | 段纪俊, 陈万青, 张思维. 中国恶性肿瘤死亡率的国际比较[J]. 中国社会医学杂志, 2009, 26(6): 377-378. |
2. | Chen WQ, Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China [J]. Thoracic Cancer, 2010, 1(1): 35-40. |
3. | Van’t Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer [J]. Cancer J, 2011, 17(1): 3-10. |
4. | Fujikawa A, Takiguchi Y, Mizuno S, et al. Lung cancer screening--comparison of computed tomography and X-ray [J]. Lung Cancer, 2008, 61(2): 195-201. |
5. | 卢先锋, 杨雪琴, 张志敏, 等. 肺癌血清肿瘤标志物meta分析[J]. 中国肺癌杂志, 2010, 13(12):1136-1140. |
6. | 赵肖, 王孟昭. 肺癌血清肿瘤标志物的临床意义[J]. 中国肺癌杂志, 2011, 14(3): 286-291. |
7. | Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer[J]. Lung Cancer, 2010, 67(2): 170-176. |
8. | Neumann T, Meyer M, Patten FW, et al. Premalignant and malignant cells in sputum from lung cancer patients[J]. Cancer, 2009, 117(6): 473-481. |
9. | 姜勇, 晋萍, 常润生, 等. 肺癌不同阳性标准痰细胞学筛查方法的灵敏度和特异度分析[J]. 中华预防医学杂志, 2011, 45(7): 605-608. |
10. | Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape[J]. Nat Immunol, 2002, 3(11): 991-998. |
11. | Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting [J]. Annu Rev Immunol, 2004, 22: 329 -360. |
12. | Belousov PV, Kuprash DV, Nedospasov SA, et al. Autoantibodies to tumor-associated antigens as cancer biomarkers [J]. Current Mol Med, 2010, 10(2):115-122. |
13. | Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors [J]. Expert Rev Mol Diagn, 2010, 10(3): 321-328. |
14. | Liu W, Peng B, Lu Y, et al. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis[J]. Autoimmun Rev, 2011, 10(6): 331-335. |
15. | Straten Pt, Andersen MH. The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens[J]. Oncotarget, 2010, 1(4): 239-245. |
16. | Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy[J]. Bull NYU Hosp Jt Dis, 2012, 70(2): 109-114. |
17. | 姚毅冰. 肿瘤自身抗体在肺癌早期诊断中的作用[J]. 中国肺癌杂志, 2010, 13(9): 903-907. |
18. | Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer [J]. Clin Cancer Res, 2010, 16(14): 3760-3768. |
19. | Chen G, Wang X, Yu J, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma [J]. Cancer Res, 2007, 67(7): 3461-3467. |
20. | Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer [J]. Ann Oncol, 2011, 22(2): 383-389. |
21. | Cherneva R, Petrov D, Georgiev O, et al. Clinical usefulness of alpha-crystallin antibodies in non-small cell lung cancer patients[J]. Interact Cardiovasc Thorac Surg, 2010, 10(1): 14-17. |
22. | Khattar NH, Coe-Atkinson SP, Stromberg AJ, et al. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer [J]. Cancer Biol Ther, 2010, 10(3): 267-272. |
23. | Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure [J]. Thorax, 2008, 63(3): 228-233. |
24. | Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera [J]. J Clin Oncol, 2008, 26(31): 5060-5066. |
25. | Pereira-Faca SR, Kuick R, Puravs E, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer [J]. Cancer Res, 2007, 67(24): 12000-12006. |
26. | Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronicgene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J]. Cell, 1993, 75(5): 843-854. |
27. | Wiemer EA. The role of microRNAs in cancer: No small matter [J]. Eur J Cancer, 2007, 43(10): 1529-1544. |
28. | Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers [J]. Mod Pathol, 2010, 23(8):1157-1164. |
29. | Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer[J]. Lab Invest, 2011, 91(4): 579-587. |
30. | Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer[J]. PLoS One, 2012, 7(2): e32307. |
31. | Chu H, Wang M, Shi D, et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies [J]. PLoS ONE, 2011, 6(3): e18108. |
32. | Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach [J]. Clin Cancer Res, 2010, 16(2): 610-619. |
33. | Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer [J]. Clin Cancer Res, 2010, 16(2): 430-441. |
34. | Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers [J]. BMC Cancer, 2011, 11(1): 374. |
35. | Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer [J]. Int J Clinical Exp Pathol, 2011, 4(6): 575-586. |
36. | Leidinger P, Keller A, Borries A, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD [J]. Lung Cancer, 2011, 74(1): 41-47. |
37. | Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer [J]. Curr Opin Oncol, 2010, 22(6): 552- 558. |
38. | Sevli S, Uzumcu A, Solak M. The function of microRNAs, small but potent molecules, in human prostate cancer [J]. Prostate Cancer Prostatic Dis, 2010, 13(3): 208-217. |
39. | Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev, 2012, 32(2): 326-348. |
40. | Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer [J]. J Clin Oncol, 2012, 30(5): 525-532. |
41. | Li Q, Qi H, Zhou HX, et al. Detection of micrometastases in peripheral blood of non-small cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay [J]. Int J Nanomedicine, 2011, 6: 2175-2181. |
42. | Bartling B, Hofmann HS, Sohst A, et al. Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma [J]. Mol Med, 2011, 17(9-10): 980-989. |
43. | Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches[J]. J Thorac Oncol, 2012, 7(2): 306-315. |
44. | Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search AssayTM and the isolation by size of epithelial tumor cell method [J]. Int J Cancer, 2011, 129(7): 1651-1660. |
45. | Ma XL, Xiao ZL, Liu L,et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer[J]. Asian Pac J Cancer Prev, 2012, 13(4): 1137-1144. |
46. | Devriese LA, Bosma AJ, van de Heuvel MM, et al. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis[J]. Lung Cancer, 2012, 75(2): 242-247. |
47. | Kato H, Nishimura T, Hirano T, et al. A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare[J]. J Proteome Res, 2011, 10(1): 51-57. |
48. | Ostroff RM, Bigbee WL, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer [J]. PLoS One, 2010, 5(12): e15003. |
49. | Cremona M, Calabrò E, Randi G, et al. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk [J]. Cancer, 2010, 116(5): 1326-1335. |
50. | 张恒, 陈胜喜, 黄凌瑾, 等. 非小细胞肺癌血清标志物PACAP的蛋白质组学筛选和鉴定[J]. 中国肺癌杂志, 2012, 15(5): 287-293. |
51. | Yang J, Song YC, Song TS, et al. Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC) [J]. J Clin Lab Anal, 2012, 26(3): 148-154. |
52. | Du J, Yang SY, Lin XL, et al. Biomarker discovery and identification from non-small cell lung cancer sera[J]. Front Biosci (Elite Ed), 2011, 3: 1-10. |
53. | Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer [J]. J Clin Oncol, 2007, 25(35): 5578-5583. |
54. | Sreseli RT, Binder H, Kuhn M, et al. Identification of a 17-protein signature in the serum of lung cancer patients[J]. Oncol Rep, 2010, 24(1): 263-270. |
55. | Kumar S, Guleria R, Singh V, et al. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy[J]. Lung cancer, 2010, 70(2): 211-217. |
56. | Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer[J]. Lung cancer, 2009, 64(1): 92-97. |
57. | Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA [J]. Clin Cancer Res, 2011, 17(13): 4494-503. |
58. | Ulivi P, Zoli W, Calistri D, et al. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small celllung cancer patients [J]. J Cell Physiol, 2006, 206(3): 611-615. |
59. | 刘晋祎, 安倩, 许冠东, 等. 肺癌患者外周血血浆中p16基因异常甲基化的检测[J]. 中国肿瘤杂志, 2004, 26(3): 154-157. |
60. | Tsao DA, Yang MJ, Chang HJ, et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients [J]. Lung Cancer, 2010, 68(1): 51-57. |
61. | Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small cell lung cancer patients [J]. Cancer Lett, 2003, 193(2): 207-216. |
62. | Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer Patients[J]. Int J Cancer, 2003, 105(3): 361-370. |
63. | Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis [J]. Clin Cancer Res, 1999, 5(10): 2689-2692. |
64. | Vinayanuwattikun C, Sriuranpong V, Tanasanvimon S, et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(11): 1818-1825. |
65. | Bajtarevic A, Ager C, Pienz M, et al. Noninvasive detection of lung cancer by analysis of exhaled breath[J]. BMC Cancer, 2009, 9(1): 348. |
66. | Ligor M, Ligor T, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry [J]. Clin Chem LabMed, 2009, 47(5): 550-560. |
67. | Fuchs P, Loeseken C, Schubert JK, et al. Breath gas aldehydes as biomarkers of lung cancer [J]. Int J Cancer, 2010, 126(11): 2663-2670. |
68. | Skeldon KD, McMillan LC, Wyse CA, et al. Application of laser spectroscopy for measurement of exhaled ethane in patients with lung cancer [J]. Res Med, 2006, 100(2): 300-306. |
69. | 刘虎, 宋耕, 秦涛, 等. 非小细胞肺癌患者呼气中挥发性有机化合物的定量分析[J]. 中华肿瘤防治杂志, 2009, 16(23): 1857-1859. |
70. | Han W, Wang T, Reilly AA, et al. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients [J]. Respir Res, 2009, 10(1): 86. |
71. | Carpagnano GE, Foschino-Barbaro MP, Mulé G, et al. 3p micro satellite alterations in exhaled breath condensate from patients with non-small cell lung cancer [J]. Am J Respir Crit Care Med, 2005, 172(6): 738-744. |
72. | Carpagnano GE, Foschino-Barbaro MP, Spanevello A, et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer [J]. Am J Respir Crit Care Med, 2008, 177(3): 337-341. |
73. | Carpagnano GE, Spanevello A, Carpagnano F, et al. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients[J]. Lung Cancer, 2009, 64(3): 334-340. |
74. | Jungraithmayr W, Frings C, Zissel G, et al. Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma[J]. Respirology, 2008, 13(7): 1022-1027. |
75. | 陈金亮, 陈建荣, 陶一江, 等. 慢性阻塞性肺疾病患者呼出气冷凝液中白细胞三烯B4和肿瘤坏死因子-α的检测及其临床意义[J]. 中国危重病急救医学, 2008, 20(6): 357-360. |
76. | Barta I, Kullmann T, Csiszer E, et al. Analysis of cytokine pattern in exhaled breath condensate of patients with squamous cell lung carcinoma [J]. Int J Biol Markers, 2010, 25(1): 52-56. |
77. | Gessner C, Rechner B, Hammerschmidt S, et al. Angiogenic markers in breath condensate identify non-small cell lung cancer[J]. Lung Cancer, 2010, 68(2): 177-184. |
78. | Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients[J]. Oncol Res, 2007, 16(8): 375-381. |
79. | Carpagnano GE, Spanevello A, Palladino GP, et al. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: how hot is the link?[J]. Lung Cancer, 2010, 67(1): 108-113. |
80. | Barash O, Peled N, Hirsch FR, et al. Sniffing the unique “odor print” of non-small-cell lung cancer with gold nanoparticles[J]. Small, 2009, 5(22): 2618-2624. |
81. | Jiang F, Todd NW, Li R, et al. A panel of sputum-based genomic marker for early detection of lung cancer [J]. Cancer Prev Res, 2010, 3(12):1571-1578. |
82. | Jiang F, Todd NW, Qiu Q, et al. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer [J]. Lung Cancer, 2009, 66(1): 58-63. |
83. | Dimakou K, Hillas G, Bakakos P. Adenosine deaminase activity and its isoenzymes in the sputum of patients with pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2009, 13(6): 744-748. |
84. | Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers [J]. Int J Cancer, 2010, 127(12): 2870-2878. |
85. | 李红梅, 付军桦, 修元德. 端粒酶与CYFRA21-1联合测定对肺癌所致恶性胸腔积液同良性胸腔积液鉴别的诊断意义[J]. 中国肺癌杂志, 2010, 13(6): 652-654. |
86. | Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers [J]. Mod Pathol, 2010, 23(8): 1157-1164. |
87. | Hsu HS, Chen TP, Wen CK, et al. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment[J]. J Pathol, 2007, 213(4): 412-419. |
88. | Hillas G, Moschos C, Dimakou K, et al. Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients[J]. Scand J Clin Lab Invest, 2008, 68(7): 542-547. |
89. | Pio R, Garcia J, Corrales L, et al. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer[J]. Cancer Epidemiol, Biomarkers Prev, 2010, 19(10): 2665-2672. |
- 1. 段纪俊, 陈万青, 张思维. 中国恶性肿瘤死亡率的国际比较[J]. 中国社会医学杂志, 2009, 26(6): 377-378.
- 2. Chen WQ, Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China [J]. Thoracic Cancer, 2010, 1(1): 35-40.
- 3. Van’t Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer [J]. Cancer J, 2011, 17(1): 3-10.
- 4. Fujikawa A, Takiguchi Y, Mizuno S, et al. Lung cancer screening--comparison of computed tomography and X-ray [J]. Lung Cancer, 2008, 61(2): 195-201.
- 5. 卢先锋, 杨雪琴, 张志敏, 等. 肺癌血清肿瘤标志物meta分析[J]. 中国肺癌杂志, 2010, 13(12):1136-1140.
- 6. 赵肖, 王孟昭. 肺癌血清肿瘤标志物的临床意义[J]. 中国肺癌杂志, 2011, 14(3): 286-291.
- 7. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer[J]. Lung Cancer, 2010, 67(2): 170-176.
- 8. Neumann T, Meyer M, Patten FW, et al. Premalignant and malignant cells in sputum from lung cancer patients[J]. Cancer, 2009, 117(6): 473-481.
- 9. 姜勇, 晋萍, 常润生, 等. 肺癌不同阳性标准痰细胞学筛查方法的灵敏度和特异度分析[J]. 中华预防医学杂志, 2011, 45(7): 605-608.
- 10. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape[J]. Nat Immunol, 2002, 3(11): 991-998.
- 11. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting [J]. Annu Rev Immunol, 2004, 22: 329 -360.
- 12. Belousov PV, Kuprash DV, Nedospasov SA, et al. Autoantibodies to tumor-associated antigens as cancer biomarkers [J]. Current Mol Med, 2010, 10(2):115-122.
- 13. Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors [J]. Expert Rev Mol Diagn, 2010, 10(3): 321-328.
- 14. Liu W, Peng B, Lu Y, et al. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis[J]. Autoimmun Rev, 2011, 10(6): 331-335.
- 15. Straten Pt, Andersen MH. The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens[J]. Oncotarget, 2010, 1(4): 239-245.
- 16. Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy[J]. Bull NYU Hosp Jt Dis, 2012, 70(2): 109-114.
- 17. 姚毅冰. 肿瘤自身抗体在肺癌早期诊断中的作用[J]. 中国肺癌杂志, 2010, 13(9): 903-907.
- 18. Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer [J]. Clin Cancer Res, 2010, 16(14): 3760-3768.
- 19. Chen G, Wang X, Yu J, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma [J]. Cancer Res, 2007, 67(7): 3461-3467.
- 20. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer [J]. Ann Oncol, 2011, 22(2): 383-389.
- 21. Cherneva R, Petrov D, Georgiev O, et al. Clinical usefulness of alpha-crystallin antibodies in non-small cell lung cancer patients[J]. Interact Cardiovasc Thorac Surg, 2010, 10(1): 14-17.
- 22. Khattar NH, Coe-Atkinson SP, Stromberg AJ, et al. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer [J]. Cancer Biol Ther, 2010, 10(3): 267-272.
- 23. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure [J]. Thorax, 2008, 63(3): 228-233.
- 24. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera [J]. J Clin Oncol, 2008, 26(31): 5060-5066.
- 25. Pereira-Faca SR, Kuick R, Puravs E, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer [J]. Cancer Res, 2007, 67(24): 12000-12006.
- 26. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronicgene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J]. Cell, 1993, 75(5): 843-854.
- 27. Wiemer EA. The role of microRNAs in cancer: No small matter [J]. Eur J Cancer, 2007, 43(10): 1529-1544.
- 28. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers [J]. Mod Pathol, 2010, 23(8):1157-1164.
- 29. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer[J]. Lab Invest, 2011, 91(4): 579-587.
- 30. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer[J]. PLoS One, 2012, 7(2): e32307.
- 31. Chu H, Wang M, Shi D, et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies [J]. PLoS ONE, 2011, 6(3): e18108.
- 32. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach [J]. Clin Cancer Res, 2010, 16(2): 610-619.
- 33. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer [J]. Clin Cancer Res, 2010, 16(2): 430-441.
- 34. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers [J]. BMC Cancer, 2011, 11(1): 374.
- 35. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer [J]. Int J Clinical Exp Pathol, 2011, 4(6): 575-586.
- 36. Leidinger P, Keller A, Borries A, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD [J]. Lung Cancer, 2011, 74(1): 41-47.
- 37. Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer [J]. Curr Opin Oncol, 2010, 22(6): 552- 558.
- 38. Sevli S, Uzumcu A, Solak M. The function of microRNAs, small but potent molecules, in human prostate cancer [J]. Prostate Cancer Prostatic Dis, 2010, 13(3): 208-217.
- 39. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev, 2012, 32(2): 326-348.
- 40. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer [J]. J Clin Oncol, 2012, 30(5): 525-532.
- 41. Li Q, Qi H, Zhou HX, et al. Detection of micrometastases in peripheral blood of non-small cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay [J]. Int J Nanomedicine, 2011, 6: 2175-2181.
- 42. Bartling B, Hofmann HS, Sohst A, et al. Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma [J]. Mol Med, 2011, 17(9-10): 980-989.
- 43. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches[J]. J Thorac Oncol, 2012, 7(2): 306-315.
- 44. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search AssayTM and the isolation by size of epithelial tumor cell method [J]. Int J Cancer, 2011, 129(7): 1651-1660.
- 45. Ma XL, Xiao ZL, Liu L,et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer[J]. Asian Pac J Cancer Prev, 2012, 13(4): 1137-1144.
- 46. Devriese LA, Bosma AJ, van de Heuvel MM, et al. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis[J]. Lung Cancer, 2012, 75(2): 242-247.
- 47. Kato H, Nishimura T, Hirano T, et al. A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare[J]. J Proteome Res, 2011, 10(1): 51-57.
- 48. Ostroff RM, Bigbee WL, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer [J]. PLoS One, 2010, 5(12): e15003.
- 49. Cremona M, Calabrò E, Randi G, et al. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk [J]. Cancer, 2010, 116(5): 1326-1335.
- 50. 张恒, 陈胜喜, 黄凌瑾, 等. 非小细胞肺癌血清标志物PACAP的蛋白质组学筛选和鉴定[J]. 中国肺癌杂志, 2012, 15(5): 287-293.
- 51. Yang J, Song YC, Song TS, et al. Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC) [J]. J Clin Lab Anal, 2012, 26(3): 148-154.
- 52. Du J, Yang SY, Lin XL, et al. Biomarker discovery and identification from non-small cell lung cancer sera[J]. Front Biosci (Elite Ed), 2011, 3: 1-10.
- 53. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer [J]. J Clin Oncol, 2007, 25(35): 5578-5583.
- 54. Sreseli RT, Binder H, Kuhn M, et al. Identification of a 17-protein signature in the serum of lung cancer patients[J]. Oncol Rep, 2010, 24(1): 263-270.
- 55. Kumar S, Guleria R, Singh V, et al. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy[J]. Lung cancer, 2010, 70(2): 211-217.
- 56. Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer[J]. Lung cancer, 2009, 64(1): 92-97.
- 57. Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA [J]. Clin Cancer Res, 2011, 17(13): 4494-503.
- 58. Ulivi P, Zoli W, Calistri D, et al. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small celllung cancer patients [J]. J Cell Physiol, 2006, 206(3): 611-615.
- 59. 刘晋祎, 安倩, 许冠东, 等. 肺癌患者外周血血浆中p16基因异常甲基化的检测[J]. 中国肿瘤杂志, 2004, 26(3): 154-157.
- 60. Tsao DA, Yang MJ, Chang HJ, et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients [J]. Lung Cancer, 2010, 68(1): 51-57.
- 61. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small cell lung cancer patients [J]. Cancer Lett, 2003, 193(2): 207-216.
- 62. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer Patients[J]. Int J Cancer, 2003, 105(3): 361-370.
- 63. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis [J]. Clin Cancer Res, 1999, 5(10): 2689-2692.
- 64. Vinayanuwattikun C, Sriuranpong V, Tanasanvimon S, et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(11): 1818-1825.
- 65. Bajtarevic A, Ager C, Pienz M, et al. Noninvasive detection of lung cancer by analysis of exhaled breath[J]. BMC Cancer, 2009, 9(1): 348.
- 66. Ligor M, Ligor T, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry [J]. Clin Chem LabMed, 2009, 47(5): 550-560.
- 67. Fuchs P, Loeseken C, Schubert JK, et al. Breath gas aldehydes as biomarkers of lung cancer [J]. Int J Cancer, 2010, 126(11): 2663-2670.
- 68. Skeldon KD, McMillan LC, Wyse CA, et al. Application of laser spectroscopy for measurement of exhaled ethane in patients with lung cancer [J]. Res Med, 2006, 100(2): 300-306.
- 69. 刘虎, 宋耕, 秦涛, 等. 非小细胞肺癌患者呼气中挥发性有机化合物的定量分析[J]. 中华肿瘤防治杂志, 2009, 16(23): 1857-1859.
- 70. Han W, Wang T, Reilly AA, et al. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients [J]. Respir Res, 2009, 10(1): 86.
- 71. Carpagnano GE, Foschino-Barbaro MP, Mulé G, et al. 3p micro satellite alterations in exhaled breath condensate from patients with non-small cell lung cancer [J]. Am J Respir Crit Care Med, 2005, 172(6): 738-744.
- 72. Carpagnano GE, Foschino-Barbaro MP, Spanevello A, et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer [J]. Am J Respir Crit Care Med, 2008, 177(3): 337-341.
- 73. Carpagnano GE, Spanevello A, Carpagnano F, et al. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients[J]. Lung Cancer, 2009, 64(3): 334-340.
- 74. Jungraithmayr W, Frings C, Zissel G, et al. Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma[J]. Respirology, 2008, 13(7): 1022-1027.
- 75. 陈金亮, 陈建荣, 陶一江, 等. 慢性阻塞性肺疾病患者呼出气冷凝液中白细胞三烯B4和肿瘤坏死因子-α的检测及其临床意义[J]. 中国危重病急救医学, 2008, 20(6): 357-360.
- 76. Barta I, Kullmann T, Csiszer E, et al. Analysis of cytokine pattern in exhaled breath condensate of patients with squamous cell lung carcinoma [J]. Int J Biol Markers, 2010, 25(1): 52-56.
- 77. Gessner C, Rechner B, Hammerschmidt S, et al. Angiogenic markers in breath condensate identify non-small cell lung cancer[J]. Lung Cancer, 2010, 68(2): 177-184.
- 78. Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients[J]. Oncol Res, 2007, 16(8): 375-381.
- 79. Carpagnano GE, Spanevello A, Palladino GP, et al. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: how hot is the link?[J]. Lung Cancer, 2010, 67(1): 108-113.
- 80. Barash O, Peled N, Hirsch FR, et al. Sniffing the unique “odor print” of non-small-cell lung cancer with gold nanoparticles[J]. Small, 2009, 5(22): 2618-2624.
- 81. Jiang F, Todd NW, Li R, et al. A panel of sputum-based genomic marker for early detection of lung cancer [J]. Cancer Prev Res, 2010, 3(12):1571-1578.
- 82. Jiang F, Todd NW, Qiu Q, et al. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer [J]. Lung Cancer, 2009, 66(1): 58-63.
- 83. Dimakou K, Hillas G, Bakakos P. Adenosine deaminase activity and its isoenzymes in the sputum of patients with pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2009, 13(6): 744-748.
- 84. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers [J]. Int J Cancer, 2010, 127(12): 2870-2878.
- 85. 李红梅, 付军桦, 修元德. 端粒酶与CYFRA21-1联合测定对肺癌所致恶性胸腔积液同良性胸腔积液鉴别的诊断意义[J]. 中国肺癌杂志, 2010, 13(6): 652-654.
- 86. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers [J]. Mod Pathol, 2010, 23(8): 1157-1164.
- 87. Hsu HS, Chen TP, Wen CK, et al. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment[J]. J Pathol, 2007, 213(4): 412-419.
- 88. Hillas G, Moschos C, Dimakou K, et al. Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients[J]. Scand J Clin Lab Invest, 2008, 68(7): 542-547.
- 89. Pio R, Garcia J, Corrales L, et al. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer[J]. Cancer Epidemiol, Biomarkers Prev, 2010, 19(10): 2665-2672.
-
Previous Article
体检纠纷常见原因及防范措施 -
Next Article
食管引流型喉罩的临床应用进展